2006;17:854–62.PubMedCrossRef”
“Erratum to: Clin Exp Nephrol
DOI 10.1007/s10157-013-0800-1 The original version of this article unfortunately contained errors. In the “Methods” section of the main text, under the heading “Participants”, the sentences that begin with “Remission” and “No response” should read: Remission was defined as complete (Up/Uc <0.2 mg/mg) or partial (Up/Uc between 0.2 and 2 mg/mg, serum albumin >2.5 g/dL, and no edema). No response was the presence of nephrotic range proteinuria (Up/Uc >2 mg/mg), serum albumin <2.5 g/dL, or edema. In Table 2, in the first column, for the line “Spot Up/Uc”, the unit should be “mg/mg”. In Table 3, in the first column, for the line “Total duration of illness (years)”, the value of Ilomastat SRNS without subclinical hypothyroidism, and the unit for the line “Cumulative dose of prednisolone” were shown incorrectly. selleck inhibitor The corrected tables are as follows: Table 2 Biochemical parameters in children with SRNS and controls SRNS (n = 20) Controls (n = 20) P value Blood urea (mg/dL) 22.00 (15.0–49.0)
19.50 (10.0–31.0) 0.162 Se creatinine (mg/dL) 0.612 ± 0.203 0.575 ± 0.18 0.547 Se albumin (g/dL) 3.54 ± 0.95 4.07 ± 0.35 0.026 Se cholesterol (g/dL) 171.0 (83–387) 130.0 (91–214) 0.002 Spot Up/Uc (mg/mg) 0.18 (0.06– 2.0) 0.15 (0.04–0.26) 0.037 FT3 (pg/dL) 3.00 (0.9–4.9) 3.3 (2.4–4.5) 0.695 FT4 (ng/dL) 1.16 (0.8–4.6) 1.2 (0.8–1.8) 0.694 TSH (mIU/L) 3.9 (0.5–13) 2.05 (0.6–3.4) 0.06 Values are expressed in mean ± SD or median (range) as appropriate Table 3 Disease profile in SRNS children with and without subclinical hypothyroidism SRNS with subclinical hypothyroidism (n = 6) SRNS without subclinical hypothyroidism (n = 14) P value Age of onset of NS (years) 2.50 (1.29–4.88) 3.67 (1.88–8.25) 0.300 Age of onset of SRNS (years) 3.75 (1.88–10.5) 7.35 (2.88–12.00) 0.364 Initial (IR)/late resistance (LR) 2/4 3/11 0.613 Duration of onset of SRNS to thyroid status evaluation (years) 1.25 (0.33–3.94) 1.82 (1.38–1.93)
0.534 Total duration of illness (years) 3.00 (2.71–8.38) 2.75 (1.9–4.20) 0.384 Cumulative dose of prednisolone (mg/kg/year)a Sorafenib 145.28 ± 34.29 186.89 ± 82.60 0.04 Se albumin (g/dL)a 3.3 ± 0.94 3.75 ± 0.77 0.72 Se cholesterol (g/dL)a 199 ± 33.14 178.28 ± 69.89 0.83 Values are expressed in median (range) aMean ± SD”
“Introduction The primary abnormal manifestation of immunoglobulin A nephropathy (IgAN) is recurring bouts of hematuria with or without proteinuria. From clinical {Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleck Anti-infection Compound Library|Selleck Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Selleckchem Anti-infection Compound Library|Selleckchem Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|Anti-infection Compound Library|Antiinfection Compound Library|buy Anti-infection Compound Library|Anti-infection Compound Library ic50|Anti-infection Compound Library price|Anti-infection Compound Library cost|Anti-infection Compound Library solubility dmso|Anti-infection Compound Library purchase|Anti-infection Compound Library manufacturer|Anti-infection Compound Library research buy|Anti-infection Compound Library order|Anti-infection Compound Library mouse|Anti-infection Compound Library chemical structure|Anti-infection Compound Library mw|Anti-infection Compound Library molecular weight|Anti-infection Compound Library datasheet|Anti-infection Compound Library supplier|Anti-infection Compound Library in vitro|Anti-infection Compound Library cell line|Anti-infection Compound Library concentration|Anti-infection Compound Library nmr|Anti-infection Compound Library in vivo|Anti-infection Compound Library clinical trial|Anti-infection Compound Library cell assay|Anti-infection Compound Library screening|Anti-infection Compound Library high throughput|buy Antiinfection Compound Library|Antiinfection Compound Library ic50|Antiinfection Compound Library price|Antiinfection Compound Library cost|Antiinfection Compound Library solubility dmso|Antiinfection Compound Library purchase|Antiinfection Compound Library manufacturer|Antiinfection Compound Library research buy|Antiinfection Compound Library order|Antiinfection Compound Library chemical structure|Antiinfection Compound Library datasheet|Antiinfection Compound Library supplier|Antiinfection Compound Library in vitro|Antiinfection Compound Library cell line|Antiinfection Compound Library concentration|Antiinfection Compound Library clinical trial|Antiinfection Compound Library cell assay|Antiinfection Compound Library screening|Antiinfection Compound Library high throughput|Anti-infection Compound high throughput screening| practice, it is known that approximately 30–40 % of IgAN patients progress to end-stage kidney disease within 20 years [1, 2], whereas 10–20 % of patients show spontaneous clinical remission [1–5].